AbCellera says Phase 2 trial shows ABCL635 cuts menopausal hot flashes after single dose
ABCL•Investor call scheduled
An investor conference call is scheduled for today at 7:30 a.m. ET to discuss the data.
Phase 2 data from ABCL635 trial
AbCellera reported positive top-line Phase 2 results from its Phase 1/2 trial of ABCL635 for menopausal hot flashes.
- Results have been presented, showing a meaningful reduction in hot-flash frequency and severity versus placebo following a single dose.
- Trial readout also indicated improvements in sleep and patient-reported overall change.
- Safety profile appeared favorable over four weeks, with no serious events reported.
